rAAV.sFLT-1视网膜下基因治疗湿性年龄相关性黄斑变性1/2a期试验三年随访
该研究为1/2a期随机对照临床试验的3年随访,评估rAAV.sFLT-1基因治疗湿性年龄相关性黄斑变性的安全性和疗效。共纳入对照组13例和基因治疗组24例,治疗组接受1×10^11vg rAAV.sFLT-1视网膜下注射并按预定标准进行抗VEGF再治疗。结果显示基因治疗在老年患者中耐受性良好,但因样本量小未能明确证实生物学疗效信号。
要点
- rAAV.sFLT-1视网膜下基因治疗在老年湿性AMD患者中耐受性良好
- 3年随访中严重不良事件多数判定与研究无关
- 因样本量小,未能明确证实生物学疗效信号
核心结论
- rAAV.sFLT-1基因治疗在老年患者中耐受性良好,但样本量小,无法明确证实存在生物学疗效信号。
研究设计与样本
- 1/2a期随机对照临床试验的3年随访,对照组13例、基因治疗组24例;治疗组接受1×10^11vg rAAV.sFLT-1,第1年每月随访、之后按需每1–2个月随访,并按预定标准给予抗VEGF再治疗。
- 第12个月时将基因治疗组分为HD-1组(再治疗<2次,n=14)和HD-2组(再治疗>2次,n=10)。
主要发现
- 第1年至第3年间共报告3例不良事件和33例严重不良事件,其中对照组13例中发生15例、基因治疗组24例中发生21例。
- 除对照组1例短暂性脉络膜炎外,严重不良事件均判定与研究无关。
- 3年内对照组再治疗中位数7.0次、ETDRS字母丢失中位数7.0个;HD-1组分别为2.5次和4.0个;HD-2组分别为11.0次和7.0个。
- 维持基线视力的比例:对照组33%、HD-2组44%、HD-1组51%;HD-1组4例(34%)在3年时维持显著视力改善。
- 上述观察均无统计学显著性。
关键数值与推荐
- 基因治疗剂量为1×10^11vg rAAV.sFLT-1视网膜下注射。
- 再治疗分组界值:HD-1为再治疗<2次,HD-2为再治疗>2次。
- 疗效观察指标包括再治疗次数中位数、ETDRS字母丢失中位数、中心点厚度波动及维持基线视力比例。
临床怎么用
- 提示rAAV.sFLT-1视网膜下基因治疗在老年湿性AMD患者中安全性可接受,可作为后续更大样本试验的安全性参考。
- 因疗效信号未达统计学显著,尚不能据此改变当前抗VEGF治疗策略。
局限性
- 样本量小(对照组13例、基因治疗组24例),无法明确证实生物学疗效信号。
- 观察性结果均无统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the safety and the 3-year results of combined phase 1 and 2a randomized controlled trials of rAAV.sFLT-1 gene therapy (GT) for wet age-related macular degeneration. DESIGN: Phase 1/2a clinical trial. METHODS: Patients were prospectively randomized into control (n = 13) and GT (n = 24) groups. GT patients received 1X1011vg rAAV.sFLT-1 and were seen every month for 1 year then as needed every 1 to 2 months. They were given retreatment anti-vascular endothelial growth factor injections according to predetermined criteria. At 12 months, GT patients were divided into 2 groups: HD-1 (n = 14), requiring <2, and HD-2 (n = 10), requiring >2 retreatments. RESULTS: Between 1 year and 3 years there were 3 adverse events (AEs) and 33 serious AEs reported. Of these, 15 occurred in the 13 control subjects and 21 in the 24 GT patients. Except for 1 case of transient choroiditis in a control patient, serious AEs were deemed to be unrelated to the study. Control patients received a median of 7.0 retreatments and lost a median of 7.0 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, HD-1 patients received a median of 2.5 retreatments and lost a median of 4.0 ETDRS letters, and HD-2 patients received a median of 11.0 retreatments and lost a median of 7.0 ETDRS letters over 3 years. Center point thickness fluctuated. Thirty-three percent of control subjects, 44% of HD-2 patients, and 51% of HD-1 patients showed maintenance of baseline visual acuity. Four HD-1 patients (34%) maintained significant visual improvement at 3 years. None of these observations were statistically significant. CONCLUSIONS: Given the small number of patients, this study was unable to unequivocally confirm the existence of a biologic efficacy signal; however, it confirmed that rAAV.sFLT-1 gene delivery was well tolerated among the elderly.
引用
- Rakoczy EP, Magno AL, Lai CM, et al. Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration. Am J Ophthalmol. 2019. PMID: 30878487. doi:10.1016/j.ajo.2019.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。